Neurogene, Inc./$NGNE
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Neurogene, Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
- Ticker
- $NGNE
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 131
- Headquarters
- New York, United States
- Website
- www.neurogene.com
Neurogene, Inc. Metrics
BasicAdvanced
$513M
-
-$5.04
1.95
-
Price and volume
Market cap
$513M
Beta
1.95
52-week high
$43.66
52-week low
$15.93
Average daily volume
312K
Financial strength
Current ratio
10.645
Quick ratio
10.501
Long term debt to equity
0.024
Total debt to equity
0.038
Interest coverage (TTM)
-40,409.00%
Profitability
EBITDA (TTM)
-117.99
Management effectiveness
Return on assets (TTM)
-27.97%
Return on equity (TTM)
-45.32%
Valuation
Price to book
1.87
Price to tangible book (TTM)
1.87
Price to free cash flow (TTM)
-6.442
Free cash flow yield (TTM)
-15.52%
Free cash flow per share (TTM)
-3.982
Growth
Earnings per share change (TTM)
17.26%
3-year earnings per share growth (CAGR)
-15.36%
What the Analysts think about Neurogene, Inc.
Analyst ratings (Buy, Hold, Sell) for Neurogene, Inc. stock.
Analyst projections of the future price of Neurogene, Inc. stock.
Bulls say / Bears say
In the Phase 1/2 trial, all 10 participants improved on the CGI-I scale and gained at least one developmental milestone, with 47 milestones gained overall and no milestone losses through follow-up of up to 30 months. That is an encouraging early efficacy signal in a serious condition with high unmet need. (Neurogene)
The 1E15 vg dose was generally well tolerated across 35 participants as of August, with no treatment-related serious adverse events or dose-limiting toxicities reported in the registrational trial. This helps address safety concerns, although the patient numbers remain limited. (SEC)
Neurogene completed dosing of 25 participants in its registrational trial and began commercial-scale process qualification runs. A July financing also extended its stated cash runway into the first quarter of 2029, giving it time to reach the planned 2027 trial readout. (Neurogene)
A participant died after developing a hyperinflammatory syndrome in the higher-dose 3E15 vg cohort, which Neurogene subsequently discontinued. The company reports no cases of this syndrome at the lower dose now being tested, but the fatal event underlines the potential severity of AAV-related risks. (SEC)
The registrational study is open-label and single-arm, so it lacks a concurrent control group to separate treatment effects from other influences. Its primary analysis covers 24 participants after 12 months of follow-up, with topline results not expected until the second half of 2027. (SEC)
Neurogene has no product revenue and reported a second-quarter net loss of $34.5 million, up from $22.0 million a year earlier. The July share-and-warrant offering strengthened its cash position but also diluted existing shareholders, while continuing losses mean future funding needs remain possible. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 27 Oct 2026.
Neurogene, Inc. Financial Performance
Revenues and expenses
Neurogene, Inc. Earnings Performance
Company profitability
Upcoming events
No upcoming events
Neurogene, Inc. News
AllArticlesVideos
Neurogene to Participate in Upcoming Investor Conferences
Business Wire3 days ago
Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndrome
Business Wire1 week ago
Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress
Business Wire2 weeks ago
Funds containing Neurogene, Inc.
Fund name | Fund size | $NGNE weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.03% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.03% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.